Remus Pharmaceuticals Limited — Others, 14-04-2025: Certificate under SEBI (Depositories and Participants) Regulations, 2018

Remus Pharmaceuticals has announced a board meeting to review the confirmation certificate from MUFG Intime India Private Limited regarding dematerialisation of securities for the quarter ended March 31, 2025. This update ensures compliance with relevant regulations and confirms that the securities received for dematerialisation have been properly processed and listed.

From an investor perspective, this announcement indicates a smooth operational process regarding securities management, contributing to a positive outlook on the company's governance and operational integrity. Investors may view this as a sign of stability in Remus Pharmaceuticals' handling of shareholder interests.